Biopreservation Market Know the diverse technological advancements in the biopreservation – BioSpace

Biopreservation is a process for conserving the tissues, organs and cells along with maintaining their integrity and functionality at different temperatures for a prolonged period of time. The necessary products for biopreservation are cryo bags, tubes, refrigerators, liquid nitrogen tanks, and freezers. These biopreservation equipment have applications in stem cell, DNA, and plasma and tissue research which helps the market to grow steadily. Various researches being carried out in cell therapy and the increasing number of bio banks also encourage market expansion. Currently, the geriatric population is affected with many disorders related to their lifestyle, namely cardiovascular disease, chronic illness, hypertension, and cancer. Biopreservation applications such as drug discovery, regenerative medicines, and bio banking help the consumers or patients during their life span and even at the time of death.

The enormous growth in the global biopreservation market is accelerated by the rising healthcare expenditure, increasing trend of conserving cord blood stem cells of newborns, and the growing investments in research and development pertaining to this field. A considerable healthcare spending is expected to drive the gene banks, bio banks and hospitals to focus on biopreservation. High costs of advanced techniques and stability issues such as tissue injury during thawing and freezing have been considered as some of the primary factors restraining the biopreservation market growth. One of the prominent names in the industry, BioLife Solutions has signed a ten years business supply agreement with Bellicum Pharmaceuticals for manufacturing, marketing of proprietary tissue and cell, and various cellular immunotherapies which target solid tumors and blood cancers. The influential regions for the biopreservation market are North America, Europe and Asia Pacific. Asia Pacific is expected to offer significant growth opportunities to market players, mostly driven by the demand arising from India and China.

Grab an exclusive PDF Brochure of this report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1340

Global Biopreservation Market: Overview

Biopreservation involves maintaining the functionality and integrity of cells, tissues, and organs outside their natural environment for an extended period of storage at different temperatures. For instance, vaccines save 3 million lives every year in the U.S, however, vaccines worth US$ 20 million are wasted each year due to inadequate storage and improper refrigeration.

Biopreservation safeguards the stability, purity, and quality of biospecimens saved in hospitals, biobanks, and gene banks. For instance, preservation of red blood cells (RBCs) is required for the ready availability of safe blood for blood transfusion needs. The biopreservation of RBCs for clinical purposes can be divided on the basis of techniques used to attain biologic stability and safeguard a viable state after extended storage times.

Global Biopreservation Market: Key Trends

The major factors driving the global biopreservation market include increasing R&D expenditure, increasing number of sperm and egg banks, increasing demand for preserving the stem cells of newborns, and rising adoption of regenerative medicine.

Buy this Premium Report @ https://www.tmrresearch.com/checkout?rep_id=1340&ltype=S

Across the world, the increasing healthcare expenditure for health and well-being will stimulate the growth of the biopreservation market. This is because healthcare expenditure accounts for a significant part of the developmental budget of most countries. According to data from the World Bank, public healthcare spending is expected to rise at a substantially high rate, which along with a substantial healthcare spending will be an important driver for gene banks, hospitals, and biobanks, which are the key end-users of biopreservation market.

A large population afflicted with chronic disorders such as cardiovascular diseases, diabetes, cancer, and hypertension as well as lifestyle diseases will bolster the markets growth. The increasing public and private spending on, medical goods and services, rising disposable income, increasing demand for biobanking services for the preservation of cells, tissues, and organs, and rising disposable income are also expected to further enhance the growth of the global biopreservation market.

Global Biopreservation Market: Market Potential

In a recent development in the biopreservation industry, BioLife Solutions, a leading name in developing, manufacturing, and marketing of proprietary cell and tissue has entered into a ten year business supply agreement with Bellicum Pharmaceuticals. The latter is a leading name in the development of cellular immunotherapies for cancers and inherited blood disorders. On account of this supply agreement, BioLifes CryoStor cell freeze media is incorporated into Bellicums production process for various cellular immunotherapies that targets blood cancers and solid tumors.

In another industry development, BioLife Solutions has entered into a partnership with transportation firm MNX and expects heightened demand for its biologistics services with the entry of more cell therapies into the clinic.

Global Biopreservation Market: Regional Outlook

The global biopreservation market can be analyzed with respect to the regional segments of North America, Europe, Asia Pacific, and Rest of the World. In North America, the U.S. accounts for almost half the revenue of the region. This is due to the increasing demand for detection of chronic diseases, government stipulations for the ethical usage of biological samples, and introduction of newer of biopreservation methodologies.

Asia Pacific biopreservation market, driven by India and China will display a sustainable growth over the next couple of years

Global Biopreservation Market: Competitive Analysis

Some of the key companies operating in the global Biopreservation market include Thermo Fischer Scientific Inc., VWR Corporation, Lifeline Scientific Inc., BioCision LLC, Custom Biogenic Systems Inc., Princeton Cryotech Inc., Sigma-Aldrich Corporation, Biolife Solutions Inc., Cesca Therapeutics Inc., Core Dynamics Ltd., and So-Low Environmental Equipment Co. Inc.

Top companies in the market are focused on mergers and acquisitions, practicing effective services, and develop new products to stay competitive in the biopreservation market. Expanding geographical reach and developing a broad product portfolio with respect to refrigerators, freezers, and consumables is also leading to the increased market share of some of the top players.

Get Table of Content of the Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=1340

This study provides a particularized anatomy according to the L.E.A.P mechanism

The regional analysis offers market assays across:

The study, prepared through the L.E.A.P mechanism adds a dimension of infallibility and assures precise information on all the growth dynamics.

Latest Biotechnology Industry Research Reports @ https://www.tmrresearch.com/biotechnology-market-reports

READ EXCLUSIVE PRESS RELEASES AND ARTICLES: https://tmrresearchblog.com/

About TMR Research

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

Rohit Bhisey

TMR Research,

3739 Balboa St # 1097,

San Francisco, CA 94121

United States

Tel: +1-415-520-1050

Visit Site: https://www.tmrresearch.com/

The rest is here:
Biopreservation Market Know the diverse technological advancements in the biopreservation - BioSpace

Reawakened immune cells attack cells tied to diseases of aging – STAT – STAT

Scientists have started to test whether natural killer, or NK, cells can be trained to go after hard-to-cure blood cancers in human patients. But making these sentinels of the innate immune system a potential boon to human health spans might be simpler: Rather than needing to be genetically engineered or primed with synthetic antibodies, they just need to be turned on.

In mice, researchers reported on Monday in the journal Med, activating NKT cells can eliminate the senescent cells partly responsible for many diseases of aging. If the results hold up, they could offer a promising alternative to senolytics experimental drugs that destroy these zombified cells that pile up and pollute your tissues as you get older. Although dozens of such drugs have postponed or even reversed diseases of aging in mouse experiments, clinical trials have thus far underwhelmed.

Its an interesting approach that works in experimental animals with two different conditions, said geriatrician James Kirkland of the Mayo Clinic, whose discovery that giving old mice senescent cell-crushing compounds makes the animals live longer, healthier lives, helped take senolytics from backwater to boomtown. Were going to need multiple ways of getting at senescent cells, he said. Any step forward is important, and this is quite a nice step forward. But he cautioned that a single senolytic strategy is unlikely to work for all age-related conditions.

advertisement

For decades, scientists had largely ignored senescent cells old and arrested in a permanent state of suspended animation dismissing them as a quirk of evolution, a clever way for the body to keep damaged cells from proliferating into cancer. But more recently, Kirkland and other researchers established that senescence is actually a driver of the decrepitude that comes with old age. As cells stop dividing, they dont exactly go dormant. In their zombie-like state, they start spewing a cocktail of toxic molecules that cause inflammation, damage surrounding tissues, and contribute to diseases like osteoarthritis, atherosclerosis, diabetes, and Alzheimers.

That realization spurred the creation of at least two dozen companies developing ways to systematically purge the body of senescent cells. Senolytics attracted this wave of investment because it promises a scintillating and fundamental shift in medicine away from the one-drug-one-target-one-disease paradigm of the last century, toward correcting a root cause behind many of them with a single treatment.

advertisement

One of those researchers is the new studys senior author, Anil Bhushan of the University of California, San Francisco. In 2019, his lab traced the progression of type 1 diabetes in mice and human pancreatic cells. They discovered that signatures of senescence preceded the onset of disease. When his team removed the senescent pancreatic cells in mice, their metabolism stabilized and their diabetes symptoms went away.

What Bhushan took away from that study was that senescence didnt just happen when the bodys biological clocks wound down too far. It occurred in acute diseases too. Thered been talk in the field that an immune surveillance system maintained tissue homeostasis, said Bhushan. We postulated that that system was failing in the disease state and gradually failing in aging, so the only time wed see senescent cells is when this system fails.

To test that hypothesis, his team first went looking for clues as to the identity of their indolent immune cells. By comparing the transcriptional profile which genes were turned on and off in senescent pancreatic cells to healthy ones, they uncovered that the senescent ones boosted production of their antigen-presenting machinery. These are the proteins that, if a cell were infected with a pathogen, would shuttle little bits of the bacteria or virus to its surface, displaying them for immune cells to find. Then they cross-referenced those results with an analysis of senescent stem cells that accumulate in the fat tissues of obese mice who are fed a chronic, high-fat diet. Those cells also upregulated antigen-presenting molecules, and one in particular: CD1d. That was the lock, said Bhushan. And once wed found it, the key was then obvious.

Only one kind of immune cell binds to CD1d invariant natural killer T cells, or iNKTs. Comprising less than 1% of all peripheral blood immune cells, iNKTs are rare but critical components of the bodys surveillance system, scanning for infected and defective cells in need of removal. When they find them, iNKTs expel torrents of cytokines, which signal to other immune cells to do the dirty work. Bhushan figured that something was interfering with that process. And though he wasnt sure what it was, he knew there was a way to fix it.

In the early 1990s, Japanese scientists from Kirin Brewerys pharmaceutical research lab, looking for anticancer treatments in the porous bodies of marine sponges collected in the Okinawan sea, purified a lipid compound called -galactosylceramide. And they discovered that when CD1d grabs onto this -GalCer lipid, it turns on iNKTs like crazy in mice.

So Bhushans team shot up some of their diet-induced obese mice with -GalCer. Within days, the levels of senescent cells in the mouse fat tissues had dropped. So did their fasting glucose. Their insulin sensitivity also improved. Their metabolism started to look normal.

To see how generalizable the effect was, they repeated the experiment with mice whose lung tissues had been damaged by a chemotherapy drug a common model for idiopathic pulmonary fibrosis, a serious and incurable human lung disease, and one of the nastier complications of Covid-19. In those mice, -GalCer successfully activated iNKTs, again resulting in the removal of senescent cells. The treated mice had fewer damaged cells, and they also lived longer than the control group.

Finally, Bhushan and his colleagues looked at how well activated iNKT cells could tell senescent human cells from healthy ones when cultured together. After 18 hours, 100% of the senescent cells had been destroyed; the vast majority of healthy cells went unscathed. That could give the iNKT approach a potential advantage over the senolytics drugs already in development.

Most of them are repackaged cancer drugs that work by flipping on senescent cells self-destruct buttons. But because zombie cells share a lot of molecular features with their fully animated counterparts, those drugs run the risk of creating lots of collateral damage. Clinical trials of one such drug, 17-DMAG, were abandoned due to toxic side effects in the kidney and brain. Other groups are trying to solve this by engineering a different kind of immune cell, the CAR-T cell, to become a better anti-aging treatment. But CAR-Ts come with their own dangerous side effects and are expensive to make.

Bhushan is optimistic that by returning the cells best trained to suss out senescent cells to the ranks of active immune duty, both these safety and cost concerns can be ameliorated. We have this built in specificity of the immune cells part of their job is telling senescent cells apart from healthy ones were just helping them do their job, he said.

Its still an open question. But clinical trials to answer it could be underway by the end of next year. Bhushans initial discoveries are now being developed by a biotech startup called Deciduous Therapeutics, which he co-founded in 2018. Deciduous is backed by 8VC, CRV, and Laura Demings Longevity Fund, and has until now, been operating in stealth. CEO and co-founder Robin Mansukhani told STAT that the company has been focusing on developing compounds that can best stimulate human iNKTs, whose receptors are structurally a bit different from those of a mouse. He expects Deciduous to file its first investigational new drug application to start human testing within the next 18 months, likely for a metabolic disease or fibrotic lung disorder.

Investors pumped the brakes on senolytics after one of the biggest and brightest stars of the nascent sector and another Longevity Fund portfolio company, Unity Biotechnology, announced last August that its lead drug candidate had failed to reduce knee pain in patients with osteoarthritis. The experimental drug was immediately and unceremoniously dumped, along with nearly one-third of Unitys staff.

But despite the recent slowdown, Mansukhani remains optimistic. The issue in the field has always been what is the actual immune system process behind senescence clearing?he said. And I feel like weve uncovered that.

Mayos Kirkland cautions that deciphering one chapter of the immune system users manual isnt likely to be the whole story. Senescence can be caused by lots of things aging, yes, but also obesity, chemotherapy drugs, and radiation. There are about 40 to 50 different things that can push a cell into a death spiral, said Kirkland. That makes it really hard to define what a senescent cell is, because its molecular makeup depends on how its senescence was induced.

But the good news, according to Kirkland, is that all the fundamental aging processes mitochondria powering down, oxygen radicals disfiguring DNA, rampant inflammation, the spiral toward senescence appear to be tightly interlinked. Its looking increasingly like if you hit one part of this network of things going on, you affect all the rest, and usually in a positive way, he said.

Kirkland, together with his team at Mayo, have had some success with a cocktail of dasatinib and quercetin. In 2019, they reported positive results from a Phase 1 pilot study of nine diabetic kidney disease patients senescent cells were reduced. A Phase 2 study is now underway. And his team has several more trials for serious conditions, including osteoporosis and Alzheimers disease, in the pipeline. Kirkland serves as a scientific adviser to a new senolytics company called NRTK Biosciences that has yet to receive funding and anti-aging supplement company Elysium Health.

But the real question for the future, said Kirkland, is which interventions can you combine to get an additive, synergistic effect? Something that actually alleviates not just one disease of aging, but many, or even all of them? Figuring out how immune cells interplay with senescence is going to be the start of looking for those combinations.

Thats whats next for Bhushans lab a painstaking process of deleting different antigen-displaying peptides across dozens of types of immune cells, and mapping out the almost infinitely complex network of interactions brewing in the toxic stew surrounding senescent cells.

We know we only have part of the story, Bhushan said. We know we can fix whatever is going wrong with iNKTs, but we still dont know exactly what that is.

Science Writer

Megan Molteni is a science writer for STAT, covering genomic medicine, neuroscience, and reproductive tech.

Trending

Measuring blood sugar in real time is a game

Measuring blood sugar in real time is a game changer for patients and a health

Comparing the Covid-19 vaccines developed by Pfizer, Moderna, and

Comparing the Covid-19 vaccines developed by Pfizer, Moderna, and Johnson & Johnson

The story of mRNA: How a once-dismissed idea became

The story of mRNA: How a once-dismissed idea became a leading technology in the Covid vaccine

Recommended

Fibrogens data manipulation scandal came with questions. There need

Fibrogens data manipulation scandal came with questions. There need to be answers

Ginkgo plans a $17.5 billion merger with SPAC that

Ginkgo plans a $17.5 billion merger with SPAC that took DraftKings public

Former Google CEO Schmidt says AI will have its

Former Google CEO Schmidt says AI will have its biggest impact in health care

Read more here:
Reawakened immune cells attack cells tied to diseases of aging - STAT - STAT

Global Stem Cell Therapy Market Analysis and Forecast (2019-2024) The Courier – The Courier

During the projected period, the world stem cell therapy market is projected to rise to a CAGR of 10.6 percent and by 2024, its market size will reach 214.5 million USD. The global demand for stem cell treatment is driven mainly by increasing awareness of the therapeutic power of stem cells and the growth of stem cell banking and processing infrastructure. Due to the easy production scale process and the growing commercialization of allogeneic treatments, the industry has experienced strong demand for allogeneic therapies in the past couple of years. Two kinds of stem cell therapy are available, allogeneic and autologous. Both are larger in the allogeneic segment, and in the coming years, are expected to expand rapidly on the market due to their comprehensive therapies, increased marketing of allogeneic products, easy processing, and the increasing number of clinical trials relating to allogeneic therapies.

For Free Sample Report-https://www.vynzresearch.com/healthcare/stem-cell-therapy-market/request-sample

The market was segmented based on therapeutic application into gastrointestinal disease, musculoskeletal disorders, cardiovascular disease, and injury. Musculoskeletal problems have led to the highest revenues in the market because musculoskeletal disorders and bone and joint diseases are on the increase and because stem cell products are available for treating musculoskeletal disease and because patients are increasingly favored for effective and early-treatment strategies.

Adipose originating from tissue-derived mesenchymal stem cells, cord blood cells, and bone marrow-derived mesenchymal stem cells were also categorized into a global stem cell therapy market by cell source. Of all categories, mesenchymal stem cells originating from bone marrow are used more and more for therapeutic purposes. The primary drivers of growth in stem cell therapy are increased awareness about the therapeutic potential of stem cell systems, development of stem cell banking and processing facilities, development of advanced cell analysis techniques based on genome, and the increase of private-government investment in stem cell therapy development. Globally, more than 50,000 transplants are carried out annually and they expand each year, according to the World Health Organization (WHO). The growth of the market also fosters a growing prevalence of chronic diseases, regulatory support across developing countries, and technical innovation in health care, cell therapy, and the discovery of new stem cell lines. Any of the diseases that can be treated by stem cell treatment may include osteoarthritis, multiple sclerosis, heart failure, hearing loss, and cerebral palsy. For example, the WHO predicts that by 2050 there will be a disabling hearing loss for an estimated 900 million people. In addition, the preventable cause of 60 percent childhood hearing loss.

Furthermore, the growth of the stem cell treatment market is stimulated by restrictions to traditional organ transplants such as organ donor dependence, risk of infection, immunosuppression rejection and threats and increasing pipelines for new applications and the development of medicinal products. North America is the the biggest market in stem cell therapy and the fastest growth in the market is seen. Factors that contribute to growth in the US stem cell therapeutics market include the an increasing number of trials to determine products therapeutic potential, increased chronic disease prevalence, a growing patient base for target diseases, increased public awareness of the therapeutics potential of therapy, and increased public-private grants for research and funding. Europe is expected to see substantial growth in stem cell therapy in the coming years.

The production of technologically innovative and advanced products is capitalized by major players in the industry, which is strengthened in the stem cell therapy market. Prestige Lyotechnology, a storage system for living cells and tissues, was introduced by Osiris Therapeutics in March 2017. In addition, MEDIPOST announced that in February 2018, the FDA has approved its drug NEUROSTEM for clinical trials for its stem cell-based Alzheimers disease drug. Some of the major players providing services are Osiris Therapeutics, Ing, RTI Surgical, Inc., MEDIPOST Co., Ltd, Nuvasive, Inc., Pharmicell, Ltd, Holostem Terapie Avanzate Srl, JCR Pharmaceuticals Co., Ltd., Anterogen Co., Ltd., and Allosaurus.

Update :

20 years old, a life-saving stem cell transplant was carried out in an anonymous donor in Germany to fight rare blood cancer. Swindons Luke Hope lost his sight in the right eye and got a 30% chance of acute lymphoblastic leukemia survival (ALL). In October, after a match was made with a man from Germany, he received a transplant at Churchill Hospital, Oxford. The UK stem cell transplantation waiting list currently has 2,000 participants.

In some private clinics patients with the healing power of stem cells charge thousands of pounds for unproven and non-regulated treatments. And some of these therapies can cause serious damage to experts. Stem cells can be used to heal damaged tissue and can transform several forms of body cells, from muscle to brain. However, only certain blood disorders, skin grafts, and repair of damaged corneas have been authorized.

For Customization Request https://www.vynzresearch.com/healthcare/stem-cell-therapy-market/customize-report

Contact Person- Kundan Kumar Email ID kundan@vynzresearch.com Source: VynZ Research https://www.vynzresearch.com/

Read more:
Global Stem Cell Therapy Market Analysis and Forecast (2019-2024) The Courier - The Courier

Cell Therapy Company Raises $160 Million to Advance iPSC-Derived Therapies to Clinic – BioSpace

Century Therapeuticsreceived a $160 million infusion of cash to advance the companys pipeline of induced pluripotent stem cell (iPSC)-derived cell therapies for cancer.

This morning, the Philadelphia-based company announced a Series C financing round that will drive its preclinical pipeline, which includes multiple iPSC-derived CAR-iT and CAR-iNK cell products, into the clinic over the next 12 months. The companys assets are designed to resist host rejection, enhance cell persistence, and allow repeat dosing to provide durable responses in all patients. Century Therapeutics, which launched in 2019, anticipates clinical testing to begin in 2022 and also predicts it will generate multiple Investigational New Drug applications over the next several years.

The companysgenetically engineered, iPSC-derived iNK and iT cell products are designed to specifically target hematologic and solid tumor cancers. Centurys iPSCs, which are stem cells that can be generated from adult stem cells, have unlimited self-renewing capacity, which enables multiple rounds of cellular engineering. According to the company, these engineering rounds will produce master cell banks of modified cells that can be expanded and differentiated into immune effector cells to supply vast amounts of allogeneic and homogeneous therapeutic products. This platform differentiates Century from competitors that are developing cell therapies made from non-renewable donor-derived cells.

The Series C financing round was led by Casdin Capital and include a number of new investors, including Fidelity Management & Research LLC, the Federated HermesKauffmannFunds, RA Capital, Logos Capital, OrbiMed,Marshall Wace, Qatar Investment Authority, Avidity Partners, and Octagon Capital.Founding investorsVersant Ventures and Leaps by Bayer also participated in the latest fundraising.

We are fortunate to be surrounded by such a top-tier group of investors, whose support will enable the acceleration of Century's technology platform into the clinic, Lalo Flores, chief executive officer of Century Therapeutics said in a statement. With this new investor partnership, we are well-positioned to capitalize on the tremendous potential of our integrated iPSC, cell engineering and manufacturing capabilities to develop safer, more effective and more affordable next generation allogeneic cancer therapies.

Eli Casdin, chief investment of Casdin Capital, who joined the Century Therapeutics Board of Directors following this Series C, said he was excited to partner with the cell therapy company.

It's a remarkable and transformative time in the field, with the ability to engineer cells for therapeutic impact now a commercial reality. At the same time, iPSC technology has matured and is now leading the transition from bespoke autologous products to off-the-shelf allogeneic ones, Casdin said in a statement.

For Century Therapeutics, the financing round was announced about one month after the company expanded its capabilities with new laboratory manufacturing facilities in Pennsylvania and New Jersey. In addition to thePennsylvaniaandNew Jerseylocations, Century has a laboratory inHamilton, Ontariospecifically focused on targeting glioblastoma, and recently opened aSeattle-based innovation hub to help advance the company's novel iPSC platform and support the continued pipeline growth and development.

Last year, Century Therapeutics acquired Empirica Therapeutics to leverage its iPSC-derived allogeneic cell therapies against glioblastoma, one of the most common types of primary brain tumor in adults.

Most Read Today

Go here to see the original:
Cell Therapy Company Raises $160 Million to Advance iPSC-Derived Therapies to Clinic - BioSpace

Retracing the Lineage of Cancer Cells – Technology Networks

Read Time:

There is no stronger risk factor for cancer than age. At the time of diagnosis, the median age of patients across all cancers is 66. That moment, however, is the culmination of years of clandestine tumor growth, and the answer to an important question has thus far remained elusive: When does a cancer first arise?

At least in some cases, the original cancer-causing mutation could have appeared as long as 40 years ago, according to a new study by researchers at Harvard Medical School and the Dana-Farber Cancer Institute.

Reconstructing the lineage history of cancer cells in two individuals with a rare blood cancer, the team calculated when the genetic mutation that gave rise to the disease first appeared. In a 63-year-old patient, it occurred at around age 19; in a 34-year-old patient, at around age 9.

The findings, published in the March 4 issue ofCell Stem Cell, add to a growing body of evidence that cancers slowly develop over long periods of time before manifesting as a distinct disease. The results also present insights that could inform new approaches for early detection, prevention, or intervention.

"For both of these patients, it was almost like they had a childhood disease that just took decades and decades to manifest, which was extremely surprising," said co-corresponding study author Sahand Hormoz, HMS assistant professor of systems biology at Dana-Farber.

"I think our study compels us to ask, when does cancer begin, and when does being healthy stop?" Hormoz said. "It increasingly appears that it's a continuum with no clear boundary, which then raises another question: When should we be looking for cancer?"

In their study, Hormoz and colleagues focused on myeloproliferative neoplasms (MPNs), a rare type of blood cancer involving the aberrant overproduction of blood cells. The majority of MPNs are linked to a specific mutation in the gene JAK2. When the mutation occurs in bone marrow stem cells, the body's blood cell production factories, it can erroneously activate JAK2 and trigger overproduction.

To pinpoint the origins of an individual's cancer, the team collected bone marrow stem cells from two patients with MPN driven by the JAK2 mutation. The researchers isolated a number of stem cells that contained the mutation, as well normal stem cells, from each patient, and then sequenced the entire genome of each individual cell.

Over time and by chance, the genomes of cells randomly acquire so-called somatic mutations--nonheritable, spontaneous changes that are largely harmless. Two cells that recently divided from the same mother cell will have very similar somatic mutation fingerprints. But two distantly related cells that shared a common ancestor many generations ago will have fewer mutations in common because they had the time to accumulate mutations separately. Cell of origin

Analyzing these fingerprints, Hormoz and colleagues created a phylogenetic tree, which maps the relationships and common ancestors between cells, for the patients' stem cells--a process similar to studies of the relationships between chimpanzees and humans, for example.

"We can reconstruct the evolutionary history of these cancer cells, going back to that cell of origin, the common ancestor in which the first mutation occurred," Hormoz said.

Combined with calculations of the rate at which mutations accumulate, the team could estimate when the JAK2 mutation first occurred. In the patient who was first diagnosed with MPN at age 63, the team found that the mutation arose around 44 years prior, at the age of 19. In the patient diagnosed at age 34, it arose at age 9.

By looking at the relationships between cells, the researchers could also estimate the number of cells that carried the mutation over time, allowing them to reconstruct the history of disease progression.

"Initially, there's one cell that has the mutation. And for the next 10 years there's only something like 100 cancer cells," Hormoz said. "But over time, the number grows exponentially and becomes thousands and thousands. We've had the notion that cancer takes a very long time to become an overt disease, but no one has shown this so explicitly until now."

The team found that the JAK2 mutation conferred a certain fitness advantage that helped cancerous cells outcompete normal bone marrow stem cells over long periods of time. The magnitude of this selective advantage is one possible explanation for some individuals' faster disease progression, such as the patient who was diagnosed with MPN at age 34.

In additional experiments, the team carried out single-cell gene expression analyses in thousands of bone marrow stem cells from seven different MPN patients. These analyses revealed that the JAK2 mutation can push stem cells to preferentially produce certain blood cell types, insights that may help scientists better understand the differences between various MPN types.

Together, the results of the study offer insights that could motivate new diagnostics, such as technologies to identify the presence of rare cancer-causing mutations currently difficult to detect, according to the authors.

"To me, the most exciting thing is thinking about at what point can we detect these cancers," Hormoz said. "If patients are walking into the clinic 40 years after their mutation first developed, could we have caught it earlier? And could we prevent the development of cancer before a patient ever knows they have it, which would be the ultimate dream?"

The researchers are now further refining their approach to studying the history of cancers, with the aim of helping clinical decision-making in the future.

While their approach is generalizable to other types of cancer, Hormoz notes that MPN is driven by a single mutation in a very slow growing type of stem cell. Other cancers may be driven by multiple mutations, or in faster-growing cell types, and further studies are needed to better understand the differences in evolutionary history between cancers.

The team's current efforts include developing early detection technologies, reconstructing the histories of greater numbers of cancer cells, and investigating why some patients' mutations never progress into full-blown cancer, but others do.

"Even if we can detect cancer-causing mutations early, the challenge is to predict which patients are at risk of developing the disease, and which are not," Hormoz said. "Looking into the past can tell us something about the future, and I think historical analyses such as the ones we conducted can give us new insights into how we could be diagnosing and intervening."

Reference:Egeren DV, Escabi J, Nguyen M, et al. Reconstructing the lineage histories and differentiation trajectories of individual cancer cells in myeloproliferative neoplasms. Cell Stem Cell. 2021;28(3):514-523.e9. doi:10.1016/j.stem.2021.02.001

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Read more:
Retracing the Lineage of Cancer Cells - Technology Networks

QC Kinetix (Myrtle Beach) Offers Stem Cells Therapy, An Alternative to Surgery For Pain Management in Myrtle Beach, SC – Press Release – Digital…

Myrtle Beach, SC - Often, the only solution is a surgical intervention for people who suffer from pain in their muscles, joints, and tendons. However, the professional team at QC Kinetix (Myrtle Beach) offers a better and non-invasive alternative by using a regenerative medicine approach to treating chronic pain and related symptoms in Myrtle Beach, SC. At QC Kinetix (Myrtle Beach), the experts stay abreast of the latest advances in the stem cell and regenerative medicine world to keep delivering effective results to patients.

Rated one of the top pain clinics in the area, QC Kinetix (Myrtle Beach) ensures that each patient who comes into the clinic is offered a unique approach to diagnosing and treating the conditions suffered. QC Kinetix (Myrtle Beach) and its team employ a cutting-edge approach to handling all pain conditions to ensure effective results.

The spokesperson for QC Kinetix (Myrtle Beach), while describing the regenerative medicine practice, said: Pain in your muscles, joints, and tendons can greatly affect your daily life and deter you from doing all the activities you once loved. Too often, surgery is looked at as the best solution to relieve pain. But surgery comes with long recovery times, drugs, and other less-than-desirable effects. The QC Kinetix Myrtle Beach office takes a different approach. We are a regenerative medicine clinic focusing on non-surgical methods of joint pain treatment.

The regenerative medical approach offered at the clinic focuses on whole-body healing using the blood, cells, and tissues that help repair all damaged areas, lessen inflammation and speed up the recovery process. Using stem cell therapy, the team at QC Kinetix (Myrtle Beach) can help patients combat all kinds of pain, especially orthopedic pain affecting the deeper areas of the muscle and tendons.

QC Kinetixs Myrtle Beach stem cells treatment is focused on different areas of the body, including the shoulder, elbow, wrists, hip, knee, ankle, feet, and low back region. Patients who suffer from chronic knee pain and instability, bone-on-bone osteoarthritis, knee arthritis, decreased range of motion, cracking, popping, or snapping sounds from the knee; torn ACL, MCL, and LCL, or torn Meniscus can take advantage of the wide range of regenerative medical treatments offered at QC Kinetix (Myrtle Beach).

Patients will be exposed to class IV laser therapy, which delivers instant relief to the affected areas; Platelet-Rich Plasma (PRP injections) which decreases inflammation and initiates the process of regeneration; regenerative cell therapy, which kickstarts the process of regeneration; stem cell therapy / BMAC, which aids in the tissue repair process, as well as ultrasounds which aid in proper diagnosis and procedural precision.

QC Kinetix (Myrtle Beach) is located at 8210 Devon Ct Suite A, Myrtle Beach, SC 29572, USA. Schedule an appointment with their providers via phone at (843) 310-2703 or visit their website.

Media Contact Company Name: QC Kinetix (Myrtle Beach) Contact Person: Adam Rose Email: Send Email Phone: (843) 310-2703 Address:8210 Devon Ct Suite A City: Myrtle Beach State: SC Country: United States Website: https://qckinetix.com/myrtle-beach/

See more here:
QC Kinetix (Myrtle Beach) Offers Stem Cells Therapy, An Alternative to Surgery For Pain Management in Myrtle Beach, SC - Press Release - Digital...

Caribou nets $115M to boost CRISPR tech, advance off-the-shelf cell therapies – FierceBiotech

On the heels of a new partnership with AbbVie, Caribou Biosciences is reeling in $115 million to keep improving its CRISPR technology and shepherd its pipeline of allogeneic, or off-the-shelf, cell therapies into and through the clinic.

Caribous most advanced program is CB-101, an anti-CD19 CAR-T therapy that's in phase 1 in B cell non-Hodgkin lymphoma. Its second program, CB-011, is a BCMA-targeting CAR-T in development for the treatment of multiple myeloma. A third asset targets CD371 for the treatment of acute myeloid leukemia. The company is developing all three programs for patients whose cancer has come back despite undergoing other treatments or did not respond to those treatments in the first place.

RELATED: After ditching Editas, AbbVie taps Caribou for new CRISPR, CAR-T pact

Learn about the key factors that are essential to creating a collaborative and productive working relationship to advance pre-clinical drug discovery programs.

The FDA has approved four CAR-T treatments for blood cancers from Novartis, Gileads Kite unit and Bristol Myers Squibb, but all four treatments are autologous, meaning they are made with a patients own cells. Caribou and other companies taking the allogeneic tack are building their treatments with donor cells in hopes that this will clear some hurdles that come with the autologous route.

Autologous treatments can be complex and time-consuming to makecells must be taken out of the patient, modified to fight cancer and then put back into the patientand some patients simply dont have that much time. Other patients may not have enough T cells, or T cells of good enough quality, to make those treatments.

And Caribou isnt stopping at CAR-T. It is also working on an allogeneic natural killer cell therapy derived from induced pluripotent stem cells for solid tumors.

Caribou has built a remarkable and highly differentiated technology platform along with a pipeline of novel therapeutic candidates which hold breakthrough potential, said Santhosh Palani, Ph.D., partner at PFM Health Sciences, who joined Caribous board as part of the financing.

RELATED: Bristol Myers Squibb's CAR-T liso-cel wins long-delayed FDA nod

PFM led the series C round alongside Farallon Capital Management and Ridgeback Capital Investors. Caribous backers returned for the financing, including Heritage Medical Systems, Maverick Ventures, and Pontifax Global Food and Agriculture Technology Fund, while several newcomers also joined in, including AbbVie Ventures, Janus Henderson Investors andThe Leukemia & Lymphoma Society Therapy Acceleration Program.

In addition to propelling Caribous pipeline, the capital will also bankroll the development of the CRISPR technology it uses to make its cell therapies. The funding follows the AbbVie deal, which saw Caribou snag $40 million upfront, with $300 million promised down the line.

See the original post:
Caribou nets $115M to boost CRISPR tech, advance off-the-shelf cell therapies - FierceBiotech

QC Kinetix (San Antonio) Offers Non-Surgical Regeneration Therapy To Treat Aches, Pains, and Injuries In Individuals Around San Antonio – Press…

San Antonio, CA - QC Kinetix (San Antonio) offers a range of regenerative treatments to individuals living in San Antonio and surrounding areas to treat acute and chronic pain and sports injuries. Their regenerative therapies help treat knee pain, shoulder pain, Carpal Tunnel Syndrome, Arthritis, Plantar Fasciitis, Tendonitis, Elbow Pain, Sciatica, Finger and Toe Pain, Foot and Hand Pain, Wrist Pain, Ankle Pain, Low Back Pain, Nerve Pain, Hip Pain, Tendon, Ligament, and Muscle Pain, and Low Levels of Testosterone in individuals.

The clinic uses stem cell therapy with BMAC and other regenerative treatments like comprehensive regenerative cell therapy injections using amniotic membrane tissue, A2M therapy, and PRP therapy. The team ensures they diagnose the patients' condition and discuss the different treatment options before proceeding with treatment. If they feel any patient is not a candidate for therapy at their clinic, they advise him/her of other options.

The patients at QC Kinetix (San Antonio) range from young athletes to active senior citizens. The doctors and treatment providers have extensive therapy in pain treatment using regenerative medicine. They speak openly with patients about their symptoms and don't try to hide anything. They aim to ensure individuals can maximize their body's ability to repair and heal itself and function efficiently. This, in turn, helps improve the individuals' overall quality of life.

The talented and well-experienced treatment providers at QC Kinetix (San Antonio) know how frustrating it can get for patients with limited mobility. They know patients can get tired of taking addictive pain medications without any positive results. They realize all of these failed attempts at treating physical ailments can have a physical and emotional toll on them.

All treatment providers at QC Kinetix (San Antonio) are board-certified and have years of regenerative medicine experience. They keep themselves updated with the latest development and technology in this field and adapt depending on their condition and requirement.

All patients that visit QC Kinetix (San Antonio) are treated equally, irrespective of age and condition. Whether individuals have mild symptoms or unbearable pain, the team at QC Kinetix (San Antonio) will ensure the patient gets full attention and is treated with care. The team knows that many people get overwhelmed at the thought of surgery and will prefer another treatment option where surgery is not required. They do their best to help individuals get treated without surgery through regenerative medicine. This place is ideal for anyone looking for San Antonio stem cell treatment.

QC Kinetix (San Antonio) has successfully treated many patients from the time they have been established. All patients who get treated at this facility go back home happier and healthier than before.

QC Kinetix (San Antonio) is located at 18707 Hardy Oak Pavilion, Suite 445, San Antonio, TX, 78258. Individuals interested in knowing more about their treatments and therapies can visit their website or contact them on (210) 571-0318 to request an appointment.

Media Contact Company Name: QC Kinetix (San Antonio) Contact Person: Casey Sietsema Email: Send Email Phone: (210) 571-0318 Address:18707 Hardy Oak Blvd Suite 445 City: San Antonio State: TX Country: United States Website: https://qckinetix.com/san-antonio/

Link:
QC Kinetix (San Antonio) Offers Non-Surgical Regeneration Therapy To Treat Aches, Pains, and Injuries In Individuals Around San Antonio - Press...

New Research Study Investigates Metformin as a Therapy to Promote Brain Repair and Reduce Disability in Children and Young Adults with MS -…

February 02, 2021 06:00 ET | Source: Multiple Sclerosis Society of Canada

multilang-release

TORONTO, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Today the Multiple Sclerosis Society of Canada announced $400,000 in funding to support a pilot clinical trial to investigate the use of metformin as a therapy for children and young adults with multiple sclerosis (MS). In partnership with Stem Cell Network (SCN) and Ontario Institute for Regenerative Medicine (OIRM), this investment increases the funding for the trial to $1 million. These partnerships are critical for leveraging more research dollars and increased impact for the benefit of Canadian health. Metformin, a widely-used and safe drug prescribed for type 2 diabetes, is a therapeutic agent that may promote brain repair and reduce disability following white matter damage in people living with MS.

Damage to white matter in the brain occurs in people with MS resulting in sensory, motor, and cognitive problems. Preclinical evidence shows metformin enhances oligodendrocytes cells that produce myelin and promotes white matter repair in animal models and in youth with radiation-induced brain injury. This research aims to translate these preclinical findings from animal and human studies into clinical practice by conducting a pilot feasibility trial.

Dr. Ann Yeh (The Hospital for Sick Children [SickKids], University of Toronto) is the lead investigator of the study and she will be joined by a team of nine Canadian researchers.

Our team is very excited about being able to move this trial forward, and for the collaborations across multiple different scientific areas that the collaborative grant will allow. This is truly a team effort that started at the bench at SickKids in the lab of Dr. Freda Miller and has set the stage for a clinical trial that could potentially improve outcomes for children and young adults living with MS, says Dr. Ann Yeh, Staff Physician, Division of Neurology and Senior Associate Scientist, Neurosciences & Mental Health at SickKids.

This trial is a unique opportunity to advance novel therapies that target regeneration and repair to help reverse the progressive nature of MS by re-purposing a safe, low-cost treatment, says Dr. Pamela Valentine president and CEO, MS Society of Canada. The MS Society is thrilled to partner with SCN and OIRM in funding this project that has the potential to change the life course, and transform treatment and care for youth and people living with MS.

The trial is the outcome of several years of work and support among researchers and partners involved in this project. It is set to run for three years and aims to recruit 30 participants between the ages of 10 to 25 who have been diagnosed with MS.

To learn more about this research trial, click here.

About multiple sclerosis and the MS Society of Canada

Canada hasone ofthe highest rates of multiple sclerosisinthe world. On average,12 Canadians arediagnosed every day.MS is a chronicautoimmunedisease of the central nervous system (brain, spinal cord).It is considered an episodic disabilitymeaningthat the severity and duration of illness and disability can vary and are often followed by periods of wellness. It can also be progressive.Most people are diagnosedwith MSbetween the ages of 20 and 49 and the unpredictable effects ofthe disease willlast for the rest of their lives.The MS Society providesinformation, support and advocacy to people affected by MS,and funds research tofind the cause and cure for the disease, bringing us closer to a world free of MS. Please visitmssociety.caor call 1-800-268-7582 for more information, to get involved, or to support Canadians affected by MS bymaking a donation. Join the conversation and connect with the MS community online. Find the MS Society onTwitter,Instagramor like our page onFacebook.

About the Ontario Institute for Regenerative Medicine (OIRM)

OIRM is a non-profit stem cell institute funded in part by the Ontario government and dedicated to transforming discoveries into clinical trials and cures. Through our commitment to collaboration and partnerships, we leverage our resources to fund and support promising advances. OIRM is a passionate champion for investigators and their patients as we build a healthier future for Ontario, Canada and the world. http://www.oirm.ca

About the Stem Cell Network (SCN) Tomorrows health is here. SCN is a national non-profit that supports stem cell and regenerative medicine research, training the next generation of highly qualified personnel, and delivering outreach activities across Canada. SCNs goal is to advance science from the lab to the clinic for the benefit of Canadians. SCN has been supported by the Government of Canada since inception in 2001. This strategic funding valued at $118M has benefitted approximately 196 world-class research groups and 3,300 trainees and has catalyzed24clinical trials. stemcellnetwork.ca

CONTACT: Jennifer Asselin MS Society of Canada 1-800-268-7582 ext. 3144 jennifer.asselin@mssociety.ca

Read more from the original source:
New Research Study Investigates Metformin as a Therapy to Promote Brain Repair and Reduce Disability in Children and Young Adults with MS -...

#FillTheSeats to save lives this February with Canadian Blood Services – Sportsnet.ca

Help Fill the Seats to save lives this February!

Canadian Blood Services is encouraging new and existing blood donors to help fill up to 6,690 appointments in Calgary and to consider making a Plasma or Steam cell donation. Currently, the need for plasma and steam cell donations is urgent.

Plasma is needed more than four times what is donated in Canada. It could take over 100 plasma donations to help treat one patient for a year. These donations go to patients who need transfusions, as well as to fractionators for manufacturing specialized medicines needed by Canadians with conditions such as bleeding disorders, burns and immunodeficiency. The winter season is typically a challenging time for blood and plasma collections due to winter hazards and weather impacts.

Stem Cell transplants can treat over 80 different diseases and disorders. Each year, hundreds of patients in Canada with cancers and blood diseases need a stem cell transplant to save their life many of whom are facing challenges finding a matching donor. A stem cell transplant replaces the patients unhealthy stem cells with a matching donors healthy stem cells. There are three sources of stem cells used in transplant:

Potential volunteer stem cell donors and expectant moms can also help save lives by donating cord blood.

Blood & Plasma donations are by appointment only. To book yours go to blood.ca, right click on find a location, enter Eau Claire Market and choose Calgary permanent clinic. To learn more about Stem Cell transplants, join the stem cell registry at https://www.blood.ca/en/stemcells.

Originally posted here:
#FillTheSeats to save lives this February with Canadian Blood Services - Sportsnet.ca